Castle Biosciences (CSTL) 주식 개요
캐슬 바이오사이언스는 피부암, 바렛 식도(BE), 아토피 피부염(AD), 포도막 흑색종의 진단 및 치료를 위한 검사 솔루션을 제공하는 분자 진단 회사입니다. 자세히 보기
CSTL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Castle Biosciences, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$24.46 |
| 52주 최고가 | US$44.28 |
| 52주 최저가 | US$14.59 |
| 베타 | 1.0 |
| 1개월 변동 | 0.58% |
| 3개월 변동 | -0.12% |
| 1년 변동 | 52.11% |
| 3년 변동 | 45.68% |
| 5년 변동 | -64.65% |
| IPO 이후 변동 | 14.30% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 09
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Analysts have raised the fair value estimate for Castle Biosciences stock by $5 to $35, citing Street research that highlights quality revenue growth potential, solid gross margins, and a path toward sustainable profitability as key supports for higher price targets. Analyst Commentary Recent Street research on Castle Biosciences reflects a mix of optimism about the company’s revenue outlook and profitability path, alongside more cautious adjustments to price targets that highlight execution and valuation risks.
내러티브 업데이트 • Jun 25
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Analysts have updated their price outlook on Castle Biosciences to reflect a $44.0 target, with the shift framed by recent Street research that highlights both reduced targets from some firms in the $35 to $40 range and continued emphasis on revenue growth potential, profit prospects and a solid balance sheet. Analyst Commentary Recent Street research on Castle Biosciences presents a mix of optimism around growth and profitability alongside more cautious revisions to price targets, giving you a fuller picture of how expectations are being reset.Recent updates
내러티브 업데이트 • Jul 09
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Analysts have raised the fair value estimate for Castle Biosciences stock by $5 to $35, citing Street research that highlights quality revenue growth potential, solid gross margins, and a path toward sustainable profitability as key supports for higher price targets. Analyst Commentary Recent Street research on Castle Biosciences reflects a mix of optimism about the company’s revenue outlook and profitability path, alongside more cautious adjustments to price targets that highlight execution and valuation risks.내러티브 업데이트 • Jun 25
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Analysts have updated their price outlook on Castle Biosciences to reflect a $44.0 target, with the shift framed by recent Street research that highlights both reduced targets from some firms in the $35 to $40 range and continued emphasis on revenue growth potential, profit prospects and a solid balance sheet. Analyst Commentary Recent Street research on Castle Biosciences presents a mix of optimism around growth and profitability alongside more cautious revisions to price targets, giving you a fuller picture of how expectations are being reset.내러티브 업데이트 • Jun 08
CSTL: Test Volume Execution And 2026 Guidance Will Underpin Upside Potential
Analysts have trimmed the price target on Castle Biosciences to $44.00 from $45.88, reflecting recent target reductions from multiple firms, even as they point to what they describe as solid test volume trends and ongoing upside potential in the stock. Analyst Commentary Recent Street commentary on Castle Biosciences points to a mixed setup, with target cuts clustered in the mid US$30s to low US$40s range and a focus on how execution in core tests might support that valuation.내러티브 업데이트 • May 24
CSTL: 2026 Clinical Data And Guidance Will Support Upside Potential
Narrative Update: Castle Biosciences The updated analyst price target for Castle Biosciences shifts from $47.25 to $45.88 as analysts factor in the recent cuts in Street targets, along with views that solid Q1 volume growth in TissueCypher and DecisionDx-Melanoma still supports potential upside over time. Analyst Commentary Recent Street research on Castle Biosciences highlights a mix of optimism around execution and caution reflected in lower price targets.내러티브 업데이트 • Apr 22
CSTL: 2026 Clinical Data And Guidance Will Support Higher Confidence
Analysts have trimmed their modeled fair value for Castle Biosciences to $47.25 from $48.50 as they recalibrate long term revenue growth, profit margin, and future P/E assumptions following a mix of recent price target increases and a reduction from different research firms. Analyst Commentary Bullish Takeaways Bullish analysts who raised their price targets highlight room for upside in their models, which typically reflects confidence in the company’s ability to execute on its current pipeline and commercial plans.내러티브 업데이트 • Apr 04
CSTL: Preliminary 2025 Update Will Support Higher Confidence In 2026 Revenue
Analysts have lifted their price targets on Castle Biosciences by up to $17, reflecting updated models that now reference 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent price target changes cluster around updated 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure.Seeking Alpha • Mar 30
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Summary Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with high clinical utility, workflow integration, and payer support, targeting a large and growing melanoma market. I assign CSTL a conviction rating of 3/5, initiating a pilot position near technical support, with plans to build exposure as the market digests 2026 earnings and product adoption. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 20
CSTL: Preliminary 2025 Revenue Signals Stronger Confidence In 2026 Outlook
Analysts have lifted their price targets on Castle Biosciences by amounts ranging up to $17, pointing to updated revenue estimates through 2026 and recent preliminary 2025 revenue disclosures as key drivers of their revised outlooks. Analyst Commentary Recent research notes focus on how preliminary 2025 revenue disclosures and updated 2026 revenue estimates feed into Castle Biosciences' valuation, with several firms adjusting their price targets to reflect these updated assumptions.내러티브 업데이트 • Mar 06
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have modestly adjusted their fair value estimate for Castle Biosciences to $48.50, citing updated revenue growth and profit margin assumptions, as well as a slightly lower future P/E multiple, as reflected in recent price target increases from several firms. Analyst Commentary Recent research updates on Castle Biosciences have centered on revised revenue assumptions for 2025 and beyond, along with higher price targets that feed into the updated fair value estimate of $48.50.내러티브 업데이트 • Feb 20
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have raised their average price target on Castle Biosciences by $14, citing updated models that now rely more on 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent research updates on Castle Biosciences focus heavily on how preliminary 2025 revenue information feeds into 2026 models, which in turn support higher price targets.내러티브 업데이트 • Feb 05
CSTL: Preliminary 2025 Revenue Signals Will Support Extended 2026 Upside Potential
Narrative Update The updated analyst price target for Castle Biosciences moves from $46.00 to about $48.57. Analysts point to refreshed assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change.내러티브 업데이트 • Jan 21
CSTL: Extended 2026 Revenue View And Test Adoption Will Support Upside
Narrative Update: Castle Biosciences Analysts have lifted their fair value estimate for Castle Biosciences from US$42.50 to US$46.00, citing updated modeling that now anchors price targets on 2026 revenue expectations following preliminary 2025 revenue disclosures. Analyst Commentary Recent Street commentary around Castle Biosciences is centering on how the preliminary 2025 revenue update reshapes expectations and valuation anchors out to 2026.내러티브 업데이트 • Jan 06
CSTL: Dermatology Test Adoption And New Launches Will Support Balanced Outlook
Analysts have lifted their price target on Castle Biosciences from US$38.75 to US$42.50, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News New data from a prospective multicenter study comparing NGS-based mutation analysis with the combination of DecisionDx-UM and PRAME for uveal melanoma outcomes was published in Nature Communications, with DecisionDx-UM described as widely adopted in the U.S. standard of care and included in AJCC and NCCN guidelines (Key Developments).내러티브 업데이트 • Dec 13
CSTL: Broader Dermatology Test Adoption Will Support Balanced Long-Term Outlook
Analysts have raised their price target on Castle Biosciences to approximately 38.75 dollars from about 35.63 dollars, citing stronger expectations for revenue growth and slightly improved profit margins, despite a modestly higher discount rate and lower projected future P E multiple. What's in the News An independent expert consensus panel endorsed Castle Biosciences DecisionDx-Melanoma test as providing robust, clinically validated prognostic information that improves melanoma risk stratification and supports more precise treatment decisions (expert consensus paper).분석 기사 • Nov 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up
Despite an already strong run, Castle Biosciences, Inc. ( NASDAQ:CSTL ) shares have been powering on, with a gain of...분석 기사 • Aug 24
What Castle Biosciences, Inc.'s (NASDAQ:CSTL) 30% Share Price Gain Is Not Telling You
The Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has done very well over the last month, posting an excellent...분석 기사 • Jun 28
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • May 23
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
Unfortunately for some shareholders, the Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has dived 28% in the last...분석 기사 • Apr 16
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
While Castle Biosciences, Inc. ( NASDAQ:CSTL ) might not have the largest market cap around , it saw a double-digit...Seeking Alpha • Apr 14
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Summary Castle Biosciences offers diverse diagnostic tests, with DecisionDx-Melanoma being a key revenue driver, but faces potential Medicare reimbursement loss for DecisionDx-SCC in 2025. The company is expanding its portfolio with TissueCypher and IDgenetix, showing strong growth, though IDgenetix faces uncertain long-term performance. Castle is well capitalized with $293 million in cash, providing a strong runway, but continues to burn cash, mainly on general and admin expenses. Trading near 52-week lows, CSTL stock presents a good entry point, but investors should watch for clarity on the SCC non-coverage issue. Read the full article on Seeking Alpha분석 기사 • Feb 25
Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
새로운 내러티브 • Feb 13
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.분석 기사 • Dec 12
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Key Insights The projected fair value for Castle Biosciences is US$66.66 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Aug 16
Castle Biosciences: Inflection Into Profitability
Summary Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. Castle Biosciences faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field. Read the full article on Seeking Alpha분석 기사 • Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Celebrations may be in order for Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders, with the analysts delivering a...분석 기사 • Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders of Castle Biosciences, Inc. ( NASDAQ:CSTL ) will be pleased this week, given that the stock price is up...분석 기사 • Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders are no doubt pleased to see that the share price has bounced 28...분석 기사 • Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...주주 수익률
| CSTL | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | -1.4% | -0.4% | -2.6% |
| 1Y | 52.1% | 39.8% | 14.3% |
수익률 대 산업: CSTL은 지난 1년 동안 39.8%의 수익을 기록한 US Healthcare 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: CSTL은 지난 1년 동안 14.3%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 9.3% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: CSTL는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: CSTL의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2007 | 942 | Derek Maetzold | castlebiosciences.com |
분자 진단 기업인 캐슬 바이오사이언스는 피부암, 바렛 식도(BE), 아토피 피부염(AD), 포도막 흑색종의 진단 및 치료를 위한 검사 솔루션을 제공합니다. 회사는 침습성 피부 흑색종 환자의 감시 림프절 양성 가능성 및 전이 위험을 예측하는 위험 계층화 유전자 발현 프로파일(GEP) 테스트인 DecisionDx-Melanoma와 비이형성, 무기한 이형성 및 저등급 이형성 식도암 환자의 향후 고등급 이형성증 및 식도암 발병 가능성을 예측하는 위험 계층화 공간로믹스 테스트인 TissueCypher를 제공하고 있습니다; 12세 이상의 중등도-중증 알츠하이머병 환자를 위한 전신적 치료제 선택을 안내하기 위해 고안된 비침습적 GEP 테스트인 AdvanceAD-Tx, 피부 편평세포암종에 대한 GEP 테스트인 DecisionDx-SCC, 진단이 어려운 멜라닌세포 병변을 가진 환자에게 사용하는 진단 GEP 테스트인 MyPath 멜라노마 등이 있다. 또한 포도막 흑색종 환자의 전이 위험을 예측하는 위험도 계층화 GEP 테스트인 DecisionDx-UM도 제공합니다.
Castle Biosciences, Inc. 기초 지표 요약
| CSTL 기초 통계 | |
|---|---|
| 시가총액 | US$724.58m |
| 순이익 (TTM) | -US$12.83m |
| 매출 (TTM) | US$339.92m |
2.2x
주가매출비율(P/S)-57.8x
주가수익비율(P/E)CSTL는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| CSTL 손익계산서 (TTM) | |
|---|---|
| 매출 | US$339.92m |
| 매출원가 | US$75.18m |
| 총이익 | US$264.74m |
| 기타 비용 | US$277.57m |
| 순이익 | -US$12.83m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 30, 2026
| 주당순이익(EPS) | -0.42 |
| 총이익률 | 77.88% |
| 순이익률 | -3.78% |
| 부채/자본 비율 | 2.2% |
CSTL의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/29 10:58 |
| 종가 | 2026/07/29 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Castle Biosciences, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |